Eckert & Ziegler with Sales Growth in the First Quarter of 2022
12.05.2022 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the previous year's quarter. This earnings gap compared to the previous year is due to a one-off effect of around EUR 6.8 million in the first quarter of 2021, in which the Group sold its tumour irradiation business at a profit. Despite the pandemic and the war in Ukraine, the Q1 figures reflect a stable start to the year. … more
Eckert & Ziegler Cooperates with Czech Research Center UJF to Produce Pharmaceutical Alpha Radioisotopes
11.05.2022 / Eckert & Ziegler AG (ISIN DE0005659700, TecDAX), a specialist in medical radioisotopes, has entered into a long-term cooperation agreement with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, UJF) to produce the alpha emitter Actinium-225. The agreement envisions Eckert & Ziegler to provide the UJF research center with several million euros for investments in equipment and hot cells, as well as radium-226 as a starting material for experiments and irradiations. In return, the Eckert & Ziegler group gets exclusive access to the capacities of a pilot unit being built within the next two years close to Prague and joint rights to the process steps developed for a large-scale Ac-225 commercial production. … more
ERC Advanced Grant for cardiac research at MDC
26.04.2022 / The contractile and elastic properties of the heart are finely tuned. This is a prerequisite for the cardiac cycle and efficient adaptation. At the MDC, Michael Gotthardt investigates the underlying molecular and biomechanical mechanisms. He is awarded with an ERC Advanced Grant for this work. … more
Where science turns into business
25.04.2022 / On April 25, 2022, Federal Commissioner for East Germany, Minister of State Carsten Schneider, and Governing Mayor of Berlin Franziska Giffey visited Campus Berlin-Buch to see how the “Zukunftsort” (place of the future) is developing. … more
COVID-19 therapy: better in combination than alone
13.04.2022 / More and more drugs are available for the treatment of COVID-19. Researchers from Charité, FU and MDC in Berlin have investigated the mechanisms of action of antiviral and anti-inflammatory substances. In the journal "Molecular Therapy" they describe that a combination of both works best. … more
Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR
08.04.2022 / Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study. … more
High-ranking naked mole-rats are more resilient
06.04.2022 / Naked mole-rats are full of surprises. The latest is that higher-ranked mole-rats most likely have an immunological advantage over animals with lower social status, a discovery made by Professor Gary Lewin’s lab at the MDC. The team is now reporting its findings in Open Biology. … more
Science you can touch
05.04.2022 / Claudia Jacob is a trained biologist who has a passion for explaining how things work. As head of the Life Science Learning Lab (Gläsernes Labor) on Campus Berlin-Buch, she gives schoolchildren a hands-on opportunity to explore the life sciences – from conducting lab experiments to discussing ideas with scientists – and perhaps even a chance to become a scientist themselves one day. … more
Award-winning science communication
04.04.2022 / One of the MDC's most cited press releases last year revealed that naked mole-rats speak in different dialects. The communications team now has another reason to feel proud of this particular press release, because it has won first prize in this year's Award for Science Communication presented by science information service idw (Informationsdienst Wissenschaft). … more
Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook
30.03.2022 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million). The consolidated net income for the year reached a new record level of EUR 34.5 million (previous year: EUR 22.9 million) or EUR 1.67 per share (previous year: EUR 1.11). … more
Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials
23.03.2022 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of Alpha-9´s investigational drugs. … more
Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market
22.03.2022 / Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market. The agreement guarantees EZAG a significant share of the growing global demand for Y90-based microspheres. From its production facilities in Braunschweig and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston, and Singapore with yttrium-90. … more
Cooperation for better medical imaging
14.03.2022 / The Max Delbrück Center for Molecular Medicine and the Otto von Guericke University Magdeburg and will cooperate in the field of medical imaging in the future. A cooperation agreement was signed on Friday, 11 March 2022 at the Research Campus in Berlin-Buch. … more
Using mRNA delivery to improve muscle strength
14.03.2022 / Mutations that lead to muscle atrophy can be repaired with the gene editor CRISPR-Cas9. A team led by ECRC researcher Helena Escobar has now introduced the tool into human muscle stem cells for the first time using mRNA, thus discovering a method suitable for therapeutic applications. … more
One step closer to artificial rhino eggs
10.03.2022 / To prevent the extinction of the northern white rhino, the international consortium BioRescue is attempting to create artificial egg cells from stem cells. A team led by MDC’s Sebastian Diecke and Micha Drukker of Leiden University has now revealed in Scientific Reports that they are one step closer to achieving this goal. … more
How SARS-CoV-2 takes over the cell's protein factory
10.03.2022 / The question of how the Covid virus takes over host cells and suppresses the body's defences has been the subject of much debate. Now a research team led by Marina Chekulaeva at the MDC has pinpointed the crucial mechanism involved. Their results have been published in the journal “RNA”. … more
Always toward the arteries
28.02.2022 / Until now, it was unknown how a new blood vessel obtains the suitable diameter. A team led by MDC researcher Holger Gerhardt has published a paper in the journal "Development" outlining how targeted migration of newly formed cells from the veins toward the arteries is crucial in this process. … more
Cholesterol-lowering drugs may slow down metastase
28.02.2022 / Many people have to take statins to lower their cholesterol levels. But statins may be able to do even more: Researchers led by Ulrike Stein of the ECRC and Robert Preißner of Charité report in Clinical and Translational Medicine that these drugs inhibit a gene that promotes cancer cell metastasis. … more
What the gut reveals about the heart
21.02.2022 / Changes in the gut microbiome can ultimately lead to cardiovascular disease. Yet some of the alterations appear to normalize in chronic conditions, a team led by ECRC researcher Sofia Forslund reports in Nature Medicine. This finding may have clinical implications. … more
New subtype of Omicron on the rise
11.02.2022 / Similar to the recent situation in Denmark, a new subvariant of Omicron known as BA.2 is now spreading in Berlin. This was revealed by an analysis of wastewater samples at the MDC in cooperation with the Berliner Wasserbetriebe and the Berlin lab of the amedes Group. The rapid emergence of BA.2 could prolong the current wave of COVID-19 infection. … more
Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials
09.02.2022 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler’s therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix’s portfolio of Molecularly Targeted Radiation (MTR) investigational products. … more
ERC Proof of Concept Grant for Gaetano Gargiulo
08.02.2022 / High-throughput methods that help search for new cancer drugs often rely on oversimplified models. For example, they do not account for the most common cell states found in patients with cancer. MDC researcher Gaetano Gargiulo has now received an ERC Proof of Concept Grant to seek a solution to this problem. … more
Solving puzzles of the chloride ion channel ASOR
03.02.2022 / The chloride ion channel ASOR is found in almost all our cells. But apart from its involvement in cell death, not much is known about its physiological role. Two years ago, researchers of the FMP and MDC led by Prof. Thomas Jentsch were able to identify the gene encoding this acid-sensitive ion channel. Now, in collaboration with Prof. Long (New York), they have gained astonishing insight about its structure and activation mechanisms. The findings, now published in Science Advances, are another step on the way to solving the puzzle of ASOR. … more
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
01.02.2022 / Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, and CantonBio Deutschland GmbH, a subsidiary of Canton Biologics Co. Ltd., a leading Chinese CDMO, today announced the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH. … more
Combination is key
21.01.2022 / New treatments for lung and colon cancer? … more
Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
10.01.2022 / Insider information pursuant to Article 17 MAR … more
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
05.01.2022 / T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife. … more
Eckert & Ziegler Acquires Argentinian SPECT Specialist
04.01.2022 / Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called “cold kits” function as vectors for the in-vivo delivery of Technetium-99 to more specific biological targets such as receptors and transporters. In tandem with the generators these generic tracers are commonly also referred to as SPECT diagnostics. Worldwide they represent the most widely used class of nuclear medicine products for the detection of cancer and cardio-vascular abnormalities at all. … more
What makes the heart and gut inseparable
09.12.2021 / Cardiovascular conditions affect life in the intestines. But the opposite is also true: Bacteria in the gut influence the course of cardiovascular disease. A team led by MDC researcher Sofia Forslund reports in Nature on the opportunities and risks this presents as well as the role played by drugs. … more
How to fill a heart
02.12.2021 / Heart failure with preserved ejection fraction was previously considered largely untreatable. An MDC team led by Professor Michael Gotthardt has now succeeded for the first time in improving cardiac function with the help of a synthetic nucleic acid, as the researchers report in the journal Science Translational Medicine. … more
Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application
30.11.2021 / Eckert & Ziegler Group is pleased to announce their partnership today with the Canadian Molecular Imaging Probe Consortium (CanProbe), a leader in the advancement and commercialization of novel radiopharmaceuticals to better serve patients and with the University Health Network (UHN), Canada’s largest health research organization affiliated with the University of Toronto. The partnership involves clinical research to further advance PentixaPharm’s Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases. … more
Genome folding in the mouse brain
18.11.2021 / A team led by MDC researcher Ana Pombo has deciphered the 3D structure of the genome in three cell types of the mouse brain. They not only discovered specific folding patterns but also found that very long genes almost completely lose their compact folded structure when most at work, as they report in “Nature”. … more
Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brazil
18.11.2021 / Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm® from the Brazilian health authority ANVISA. GalliaPharm® is thus the first and currently the only pharmaceutical gallium generator approved in Brazil. … more
Eckert & Ziegler: One-Off Effects and Robust Operating Business Push Nine-Month Result to Record Level
09.11.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), achieved a record result in the first nine months of 2021 with a net profit of € 29.2 million or € 1.41 per share. By the end of September, earnings had thus already exceeded those of the entire previous year by € 11.6 million or 65%. Adjusted for the tumor irradiation business, which has been sold in the meantime, Group sales totaled € 126 million, up € 9 million or 8% on the previous year's level. … more
Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in China
05.11.2021 / Eckert & Ziegler AG (ISIN DE0005659700), a global specialist for isotope applications in medicine and industry has acquired an approximately 7,000 m² property with an expansion option for the building of its Chinese production facility in Jintan (PR China). The purchase was made through a public tender process. … more
The tricks of lymphomas
03.11.2021 / Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As the they describe in “Cell Reports”, this cancer induces changes in the large blood vessels through which immune cells normally migrate to the lymph nodes. … more
Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services
11.10.2021 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (5,000 square meters) of factory floor located at the north eastern city limit of Berlin. The group plans to use the facility for the expansion of its contract development and manufacturing services that it provides, among others, for a variety of cancer therapeutics and radio diagnostics. Up to 10 mm EUR will be invested during the next years into the renovation of the site, the set-up of new laboratories, production and clean rooms meeting Good Manufacturing Standards for the pharmaceutical industry, and the creation of high-tech workplaces. Due to its proximity to a thermal power station, the new site is expected to meet highest energy efficiencies. … more
Lighting up tumor cells
30.09.2021 / MDC PhD student Matthias Jürgen Schmitt is being honored with the Curt Meyer Memorial Prize of the Berlin Cancer Society for his achievements in cancer research. He employs molecular reporters to investigate how glioblastoma – the deadliest brain tumor of all – becomes resistant to therapies. … more
Nantes University Hospital Doses First Patients with Eckert & Ziegler’s Novel Ga-68 Imaging Agent PENTIXAFOR
27.09.2021 / The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas. The Ga-68 based radio-diagnostic promises to significantly improve the patient management for early forms of the disease by identifying the optimal therapeutic alternative. … more
BR50: Strengthen the science metropolis Berlin
24.09.2021 / With a position paper developed under the umbrella of Berlin Research 50, the non-university institutions of Berlin emphasize what is important for science in Berlin. They state ten demands that should be implemented by the future senate to strengthen Berlin as science metropolis. … more
Downtime at the nerve cell’s protein factories
15.09.2021 / A team led by MDC researcher Marina Chekulaeva has figured out why protein production slows down in the nerve cells of people suffering from Charcot-Marie-Tooth disease. This discovery could lead to a new therapeutic approach, the scientists report in the journal "Nucleic Acids Research". … more
COVID-19: What is driving the escalating hyperinflammation
13.09.2021 / The severity of COVID-19 is primary result of a dysregulated immune response. A cellular stress response mechanism plays a major role in the derailed immune response: senescence, report Clemens Schmitt and his colleagues in “Nature“. This suggests novel treatment path. … more
Disease genes help early brain development
09.09.2021 / If the cerebral hemispheres of the forebrain fail to divide properly in an unborn child, this results in holoprosencephaly. An MDC team led by Annette Hammes has discovered candidate genes that can positively influence the severity of this congenital malformation of the forebrain, as the researchers now report in the journal Development. … more
Lab Meets Teacher addresses cell diagnostics, cancer and AI
02.09.2021 / The new edition of the MDC’s “Lab Meets Teacher – Digital” further education program begins in September. The eight online LMT training sessions will give teachers insights into the latest research topics and methods – such as single-cell analysis, which is expected to deliver new understanding of disease processes. … more
Johanna Quandt-Professorship for Kathrin de la Rosa
01.09.2021 / Stiftung Charité Foundation and the Berlin Institute of Health at the Charité are continuing their format for recruiting outstanding female scientists. MDC researcher Kathrin de la Rosa is among the four new Johanna Quandt Professors. The immunologist will continue to lead her research group here. … more
A cell atlas of the pediatric heart
30.08.2021 / After providing funding for single-cell analysis of adult hearts, the Chan Zuckerberg Initiative is now supporting the creation of a cell atlas of children’s hearts. An international team led by Christine Seidman of Harvard University and Norbert Hübner of the MDC is again among the funded networks. … more
Eckert & Ziegler Starts Technetium-99 Delivery in Brazil
28.08.2021 / Eckert & Ziegler (ISIN DE0005659700, TecDAX), has started the delivery of Technetium-99 generators in Brazil. The subsidiary Eckert & Ziegler Brasil Comercial Ltda. had recently received a license from the Brazilian health authority ANVISA as the first and only private company to import and distribute technetium generators. Two leading hospitals in the greater Sao Paulo area are among the first customers, and further orders have already been placed. … more
Slow version of the glutamate receptor AMPA discovered
17.08.2021 / The glutamate receptor AMPA was previously known for its lightning-fast transmission of excitation. All the more surprising, therefore, are the results that researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin have now made: AMPA-receptors can also be extraordinarily slow. The discovery of the new type of receptor puts synaptic signaling in a whole new light. The groundbreaking findings were recently published in the journal Cell Reports. … more
Events
all events
22.06.2022, 13:00-
22.06.2022, 13:30
CampusVital LOUNGE: What the gut reveals about the heart
02.07.2022, 16:00-
02.07.2022, 23:00
Lange Nacht der Wissenschaften
31.08.2022, 09:00-
03.09.2022, 18:00
From Target to Market - The GLA Biotech & Pharma Summer School